Moderna spins-out Onkaido Therapeutics to focus on mRNA therapeutics in oncology

15 January 2014

Flush with cash as a result of its mega-million dollar deal with Alexion on the development of drugs for rare diseases and a previous accord with AstraZeneca (The Pharma Letter January 15), privately-held US start up Moderna Therapeutics has announced the creation of Onkaido Therapeutics, a new venture focused exclusively on developing mRNA-based oncology treatments.

Onkaido Therapeutics will launch with $20 million in committed capital from Moderna. The new company will focus initially on 15 preclinical drug candidates in the areas of apoptosis, central regulatory nodes and immunotherapy. Several of these candidates are already under evaluation in in vivo disease models. By establishing Onkaido as a standalone unit, Moderna intends to accelerate the development of mRNA Therapeutics for oncology and deliver the potential of these new cancer treatments to patients.

Management line up

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical